1205 related articles for article (PubMed ID: 9879825)
1. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
2. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
3. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
[TBL] [Abstract][Full Text] [Related]
4. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler HG; MacLeod RA; Uphoff CC
Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Verfaillie CM
Blood; 1998 May; 91(9):3414-22. PubMed ID: 9558400
[TBL] [Abstract][Full Text] [Related]
7. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
[TBL] [Abstract][Full Text] [Related]
8. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
9. Chromosome abnormalities in CML.
Hagemeijer A
Baillieres Clin Haematol; 1987 Dec; 1(4):963-81. PubMed ID: 3332858
[TBL] [Abstract][Full Text] [Related]
10. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.
Clarkson B; Strife A
Leukemia; 1993 Nov; 7(11):1683-721. PubMed ID: 8231240
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
[TBL] [Abstract][Full Text] [Related]
13. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
[TBL] [Abstract][Full Text] [Related]
14. Megakaryocytes carry the fused bcr-abl gene in chronic myeloid leukaemia: a fluorescence in situ hybridization analysis from bone marrow biopsies.
Nolte M; Werner M; Ewig M; von Wasielewski R; Link H; Diedrich H; Georgii A
Virchows Arch; 1996 Mar; 427(6):561-5. PubMed ID: 8605566
[TBL] [Abstract][Full Text] [Related]
15. [Progress in laboratory medicine in chronic myeloid leukemia].
Miura A
Rinsho Byori; 1998 Dec; 46(12):1226-31. PubMed ID: 9916508
[TBL] [Abstract][Full Text] [Related]
16. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
Skórski T; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.
Bedi A; Zehnbauer BA; Collector MI; Barber JP; Zicha MS; Sharkis SJ; Jones RJ
Blood; 1993 Jun; 81(11):2898-902. PubMed ID: 8499629
[TBL] [Abstract][Full Text] [Related]
18. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
19. [Chronic myeloid leukemia, biological aspects].
Costello R; Bouabdallah R; Sainty D; Gastaut JA; Gabert J
Rev Med Interne; 1996; 17(3):213-23. PubMed ID: 8734143
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
Warmuth M; Danhauser-Riedl S; Hallek M
Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
